- Results published in AAST’s Trauma Surgery & Acute Care Open Journal - - Study compared outcomes of patients treated with Symvess with patients in PROOVIT registry who were treated with vein - - In a comparison to prior results in the PROOVIT registry, outcomes for Symvess and autologous vein were similar for treatment of vascular trauma - DURHAM, N.C., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, b ...

BioHarvest Sciences Announces Strategic CDMO Partnership to Revolutionize Saffron Compound Production with Botanical SynthesisOctober 30, 2025 7:30 AM EDT | Source: BioHarvest Sciences Inc.Partnership with "Saffron Tech" to Advance Production of One of the World's Most Valuable BotanicalsManagement Concurrently Shares Third Quarter 2025 Preliminary Results and Provides Guidance for the Fourth Quarter of 2025 Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - October 30, 2025) - ...

Applied Digital Corporation ( APLD ) stock has seen quite a bit of upside since the initial deal with CoreWeave, Inc. ( CRWV ), which put them on the map in terms of lease capacity. Now, movingI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation for the rigor and challeng ...

Reference is made to the stock exchange announcement by Hofseth BioCare ASA ("HBC" or the "Company") on 27 October 2025 regarding (i) the completion of a private placement (the "Private Placement") of new shares in the Company the "Offer Shares"), the completion of which by delivery of Offer Shares in tranche 2 (the "T2 Offer Shares") is subject to, among other things, an extraordinary general meeting (the "EGM") resolving to issue the T2 Offer Shares in the Private Placement and (ii) a potential subsequent ...

This press release corrects and replaces the company’s press release issued today, 10/29, at 4:15 p.m. ET in order to correct a typographical error in the first sub-bullet under “WVE-007 (GalNAc-siRNA)” – “Next steps.” Dose-dependent mean reductions of Activin E of up to 85% one month post single dose of WVE-007 in INLIGHT clinical trial, exceeding levels that led to weight loss in preclinical models; WVE-007 is generally safe and well tolerated to date Activin E reduction in lowest dose cohort of INLIGHT ...

股票价格显著上涨的公司 - Globalink Investment Inc (NASDAQ:GLLIW) 股价上涨至0.09美元，涨幅达581.82%，交易量为450，远高于平均水平，该公司为科技领域（特别是电子商务和支付）的壳公司，股价异动可能与投机活动或潜在的业务合并消息相关 [1][6] - Cambium Networks Corporation (NASDAQ:CMBM) 股价上涨至2.66美元，涨幅达331.65%，交易量高达401,376,497，远超平均水平，股价上涨源于其Cambium ONE Network解决方案与Starlink卫星互联网服务的整合 [2][6] - Purple Biotech Ltd (NASDAQ:PPBT) 股价上涨至0.93美元，涨幅为59.74%，交易量为369,881,580，股价变动受其临床试验或战略合作的积极进展驱动 [3][6] - Ernexa Therapeutics Inc (NASDAQ:ERNA) 股价上涨至1.97美元，涨幅为57.85%，交易量为195,401,189，投资者对其创新疗法的乐观情绪推动股价 [4][6] - VSee Health, Inc (NASDAQ:VSEEW) 股价上涨至0.17美元，涨幅为49.52%，交易量为666,331，反映了投资者对远程医疗领域日益增长的兴趣 [5] 公司特定发展驱动因素 - Cambium Networks 与 Starlink 的整合旨在通过提供集中管理、多广域网优化和增强安全性来改善 Starlink 部署，体现了对公司增长前景的信心 [2] - Purple Biotech 在其CAPTN-3平台上开发的IM1240三特异性抗体达到重要生产里程碑，验证了该平台的可扩展性，并使IM1240在未来的开发中具有竞争优势 [3] - Ernexa Therapeutics 与 Cellipont Bioservices 合作，共同推进用于卵巢癌的细胞疗法ERNA-101进入临床试验，凸显了公司致力于开发针对晚期癌症和自身免疫性疾病的新型细胞疗法 [4] 行业趋势与市场动态 - 远程医疗领域因持续的医疗保健趋势而加速采用和创新，推动了相关公司如VSee Health的投资者兴趣 [5] - 壳公司（如Globalink Investment）的价格常因投机活动或潜在业务合并消息而出现波动 [1] - 公司特定发展、行业趋势和更广泛的经济因素显著影响股价，这些变化被用于衡量市场情绪和识别潜在投资机会 [5]

CARY, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced the appointment of Thomas Cusack to its Board of Directors. Mr. Cusack has extensive experience in matters related to corporate finance, investment management, and corporate governance. Mr. Cusack was appointed to the Board pursuant to the Cooperation Agreement entered into between the Company and Rubric Capital Management LP, dated as of ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Jasper (JSPR) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Jasper between November 30, 2023 and July 3, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Brag ...

Not for distribution by US newswire or in United States NESS-ZIONA, ISRAEL, Oct. 29, 2025 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), is pleased to announce that the Company intends to complete a non-brokered private placement on a commercially reasonable efforts basis (the "Offering") of up to 2,456,140 units ("Units") of the Company at a price of $0.1425 per Unit to raise gross proceeds of up to $350,000. Each Unit will consist of one common share of the Company ("Sha ...

VANCOUVER, Wash. and NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a clinical-stage biotech company advancing breakthrough therapeutics with generative AI, today announced the company will report business updates and financial and operating results for the third quarter 2025 after market close on Wednesday, November 12, 2025. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, fin ...